MA54028A1 - Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène - Google Patents

Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Info

Publication number
MA54028A1
MA54028A1 MA54028A MA54028A MA54028A1 MA 54028 A1 MA54028 A1 MA 54028A1 MA 54028 A MA54028 A MA 54028A MA 54028 A MA54028 A MA 54028A MA 54028 A1 MA54028 A1 MA 54028A1
Authority
MA
Morocco
Prior art keywords
ibuprofen
pharmaceutical composition
composition containing
acetominophen
containing acetominophen
Prior art date
Application number
MA54028A
Other languages
English (en)
Other versions
MA54028B2 (fr
Inventor
Matt Callahan
Maura Murphy
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MA54028A1 publication Critical patent/MA54028A1/fr
Publication of MA54028B2 publication Critical patent/MA54028B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formes posologiques orales solides contenant 325 mg d'acétaminophène et 97,5 mg d'ibuprofène ou 500 mg d'acétaminophène et 150 mg d'ibuprofène, l'ibuprofène ayant un [d50] compris entre 1 et 9 µm.
MA54028A 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène MA54028B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/287,836 US11197830B2 (en) 2019-02-27 2019-02-27 Pharmaceutical composition containing acetaminophen and ibuprofen
PCT/US2020/020112 WO2020176736A1 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Publications (2)

Publication Number Publication Date
MA54028A1 true MA54028A1 (fr) 2022-06-30
MA54028B2 MA54028B2 (fr) 2023-10-31

Family

ID=72140141

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54028A MA54028B2 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
MA62176A MA62176A1 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA62176A MA62176A1 (fr) 2019-02-27 2020-02-27 Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène

Country Status (23)

Country Link
US (4) US11197830B2 (fr)
EP (1) EP3930691A4 (fr)
CN (1) CN113795243A (fr)
AU (4) AU2019268077B2 (fr)
BR (1) BR112021017037A2 (fr)
CA (1) CA3131917A1 (fr)
CL (1) CL2021002252A1 (fr)
CO (1) CO2021011525A2 (fr)
CR (1) CR20210451A (fr)
EA (1) EA202192118A1 (fr)
EC (1) ECSP21072036A (fr)
GB (1) GB2595406B (fr)
IL (1) IL285866A (fr)
JO (1) JOP20210235A1 (fr)
MA (2) MA54028B2 (fr)
MX (1) MX2021010338A (fr)
NZ (1) NZ759337A (fr)
PE (1) PE20220591A1 (fr)
SG (1) SG11202109258WA (fr)
TN (1) TN2021000176A1 (fr)
TW (1) TW202045148A (fr)
UA (1) UA127775C2 (fr)
WO (1) WO2020176736A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
WO2020263947A1 (fr) * 2019-06-27 2020-12-30 Pf Consumer Healthcare 1 Llc Nouvelle composition d'ibuprofène et d'acétaminophène

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148139B2 (fr) 1972-09-30 1976-12-18
AU605538B2 (en) 1988-01-19 1991-01-17 Adcock Ingram Limited Pharmaceutical unit
CA1336687C (fr) 1989-08-23 1995-08-15 Thomas M. Tencza Mode de preparation de comprimes contenant de l'ibuprofene, de l'acetaminophere et de la cafeine, les produits ainsi obtenue et leurs applications
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5260337A (en) 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
JP3982889B2 (ja) 1997-11-28 2007-09-26 あすか製薬株式会社 イブプロフェン含有医薬製剤
US6440983B1 (en) 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
GB0414442D0 (en) 2004-06-28 2004-07-28 Borealis As Zeolite catalysts
KR101370712B1 (ko) 2004-07-07 2014-03-06 에이에프티 파마슈티칼스 리미티드 복합 조성물
KR20060072839A (ko) 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
GB0519350D0 (en) 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
WO2008079818A2 (fr) 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Administration intraveineuse de formulations analgésiques hydrosolubles
JP5148139B2 (ja) 2007-03-12 2013-02-20 パナソニック株式会社 半導体装置及びその製造方法
US20100288665A1 (en) * 2007-07-23 2010-11-18 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
TR201102810T2 (tr) 2008-10-14 2011-05-23 Aft Pharmaceuticals Limited Tıbbi bir ürün ve tedavi
DK2421513T3 (en) 2009-04-24 2018-03-26 Iceutica Pty Ltd UNKNOWN FORMULATION WITH INDOMETHACIN
CA2759104C (fr) 2009-04-24 2019-01-29 Iceutica Pty Ltd Procede d'amelioration du profil de dissolution d'une matiere biologiquement active
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
AU2011274652B2 (en) 2010-07-07 2013-08-15 Aft Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol
CL2010000738A1 (es) 2010-07-08 2011-03-25 Wockhardt Res Centre Suspension farmaceutica oral que comprende desde 100 hasta 500 mg/5ml de paracetamol, desde 40 hasta 80 mg/5ml de ibuprofeno o desde 200 hasta 400 mg/5ml de paracetamol, desde 100 hasta 200 mg/5ml de ibuprofeno y uno o mas excipientes farmaceuticamente aceptables, util para tratar el dolor pre, peri o postoperatorio.
HUE045442T2 (hu) * 2010-11-04 2019-12-30 Aft Pharmaceuticals Ltd Kombinációs készítmény
JP5830412B2 (ja) 2011-03-02 2015-12-09 ライオン株式会社 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Also Published As

Publication number Publication date
US11197830B2 (en) 2021-12-14
EP3930691A4 (fr) 2022-11-30
JOP20210235A1 (ar) 2023-01-30
MA54028B2 (fr) 2023-10-31
US20200268673A1 (en) 2020-08-27
AU2021200634B2 (en) 2022-03-10
AU2019268077A1 (en) 2020-09-10
AU2022201196A1 (en) 2022-03-17
UA127775C2 (uk) 2023-12-27
WO2020176736A1 (fr) 2020-09-03
ECSP21072036A (es) 2021-11-30
NZ759337A (en) 2023-06-30
AU2024203208A1 (en) 2024-05-30
TW202045148A (zh) 2020-12-16
IL285866A (en) 2021-10-31
GB2595406A (en) 2021-11-24
EA202192118A1 (ru) 2021-11-18
AU2021200634A1 (en) 2021-03-04
BR112021017037A2 (pt) 2021-11-09
GB202112205D0 (en) 2021-10-13
AU2019268077B2 (en) 2021-02-25
PE20220591A1 (es) 2022-04-22
CA3131917A1 (fr) 2020-09-03
MA62176A1 (fr) 2024-01-31
CL2021002252A1 (es) 2022-04-29
CN113795243A (zh) 2021-12-14
US20240091160A1 (en) 2024-03-21
US20230201125A1 (en) 2023-06-29
GB2595406B (en) 2023-05-10
MX2021010338A (es) 2022-01-07
US20220175680A1 (en) 2022-06-09
US11534407B2 (en) 2022-12-27
CO2021011525A2 (es) 2021-09-20
TN2021000176A1 (en) 2023-04-04
US11872317B2 (en) 2024-01-16
CR20210451A (es) 2021-12-02
EP3930691A1 (fr) 2022-01-05
SG11202109258WA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
WO2007016563A3 (fr) Formulations pharmaceutiques resistantes a l'alcool
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
HUP0301325A2 (hu) Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására
MA54028A1 (fr) Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène
CA2423825A1 (fr) Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
BR0213355A (pt) composições farmacêuticas
MA31706B1 (fr) Formulations galéniques de composés organiques
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
MA33060B1 (fr) Formulations galéniques de composés organiques
WO2005004915A3 (fr) Compositions contenant meloxicam
EA200600173A1 (ru) Диспергируемая во рту фармацевтическая композиция антитромботического соединения
AU2001270345A1 (en) Microsporidia isolate
EA202092349A1 (ru) Лактитол и пероральная лекарственная форма при неалкогольной жировой болезни печени
BRPI0416691A (pt) forma de preparação farmacêutica sólida
FR3083980B1 (fr) Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique
MA38093A1 (fr) Formulations à libération modifiée pour l'oprozomib
ATE547106T1 (de) Cladribin dosierschema zur behandlung von multipler sklerose